Project Grant R01AI186663

Award Date 8/6/24
Completion Date 7/31/29
Dollars Obligated $572K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Salt Lake City, UT 84112, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Program (CFDA 93.855), provides $653,693 to Emory University to conduct research on the structural details of HIV-1 virion assembly, maturation, and entry. The work will leverage cryo-electron microscopy and tomography to interrogate the molecular determinants and cellular interactions involved in the HIV-1 capsid lattice formation and...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the dynamics and evolution of HIV Gag and GagPol processing. The $752,745 award aims to use molecular dynamics simulations, single-molecule FRET imaging, and cryo-electron tomography to probe the structure and dynamics of Gag and GagPol that enable ordered processing by the viral...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $859,992 to Yale University to conduct research on the molecular mechanisms underlying HIV-1 maturation and the impact of capsid inhibitors on this process. The research aims to: 1) determine the high-resolution structural pathway of HIV-1 Gag assemblies and capsid during maturation within their native...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $220,224 to the University of Chicago to computationally investigate key morphological transitions in the HIV-1 life cycle. The research aims to gain a deeper mechanistic understanding of HIV assembly, maturation, and uncoating processes, with a focus on the roles of viral RNA, host cell factors, and...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $603,338 Project Grant to Yale University. The grant supports research to understand how the human immunodeficiency virus 1 (HIV-1) mediates fusion with host cells, specifically investigating the interactions between the viral envelope glycoprotein (Env), cellular receptors CD4 and CCR5/CXCR4, and cell membranes. Using...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $617,376 to Emory University to conduct research on the activation and maturation of the HIV-1 virus. The key objectives are to: 1) Measure the timing of protease (PR) activation relative to HIV-1 budding from the host cell, 2) Assess the rate and extent of PR substrate cleavage and correlate this with formation of...
This $775,391 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to investigate the role of the human protein galectin-9 in HIV persistence and the establishment of the long-term viral reservoir. The primary awardee, Vitalant Research Institute, will conduct in vitro studies to elucidate the molecular and immunological mechanisms underlying galectin-9's impact on the HIV reservoir. Additionally,...
This Project Grant award of $1,454,386.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports fundamental research to better understand the epigenetic regulation of the HIV-1 viral RNA cap. The research aims to define the structural basis of HIV cap hypermethylation and its linkage to modulating host innate immune signaling, with the goal of developing new treatments to neutralize deleterious...
This federal Project Grant award of $2,505,639 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand the molecular interactions between lentivirus capsids and the nuclear pore complex protein NUP358. The project aims to investigate how the binding of lentiviral capsids, including HIV-1 and HIV-2, to the RBD4-CHD didomain of NUP358 impacts viral nuclear import and replication....
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $258,200 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Colorado-Denver. The grant supports research to investigate the non-catalytic functions of HIV-1 integrase (IN) during virion maturation, including developing a biochemical model system to examine IN's ability to encapsulate viral RNA within capsid-like particles and determining cryo-EM structures of IN...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $571,685 to the University of Utah to conduct research on the architecture and dynamics of the immature HIV lattice. The primary goals are to investigate the effects of non-Gag components on the stability of the immature HIV lattice and determine how dynamics within the lattice drive the activation of HIV enzymes and the maturation process. The research is expected to inform the design of next-generation antivirals and advance the understanding of lentiviral systems. The University of Utah has also awarded a $184,601 sub-grant to The Johns Hopkins University to study the balance of structure and disorder in the immature HIV Gag lattice as part of this project. This federally-funded research aims to enhance the molecular-level comprehension of HIV assembly, release, and maturation to support the development of improved antiviral treatments and technologies.

Generated 7/1/25, 3:36 AM